Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-19
DOI
10.1186/s13045-021-01157-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
- (2021) Srdan Verstovsek et al. Future Oncology
- Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
- (2021) Francesca Palandri et al. Blood Cancer Journal
- Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
- (2021) Francesca Palandri et al. CANCER
- SOHO State of the Art Updates and Next Questions: Identifying and Treating “Progression” in Myelofibrosis
- (2021) Prithviraj Bose et al. Clinical Lymphoma Myeloma & Leukemia
- Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status
- (2021) Jean-Jacques Kiladjian et al. Clinical Lymphoma Myeloma & Leukemia
- Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.
- (2021) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
- (2021) Francisco Cervantes et al. LEUKEMIA
- Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
- (2021) Nicolaus Kröger et al. LEUKEMIA
- Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
- (2021) Léa Sureau et al. Blood Cancer Journal
- Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
- (2021) Srdan Verstovsek et al. ANNALS OF HEMATOLOGY
- SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
- (2021) Helen T. Chifotides et al. Clinical Lymphoma Myeloma & Leukemia
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication
- (2020) Bridget K. Marcellino et al. Clinical Lymphoma Myeloma & Leukemia
- Iron metabolism and iron disorders revisited in the hepcidin era
- (2020) Clara Camaschella et al. HAEMATOLOGICA
- Management of myelofibrosis after ruxolitinib failure
- (2020) Claire N Harrison et al. ANNALS OF HEMATOLOGY
- Secondary leukemia to myeloproliferative neoplasms
- (2020) Andrew Dunbar et al. BLOOD
- Current and future therapies for myelofibrosis
- (2020) Samir Asher et al. BLOOD REVIEWS
- Management of challenging myelofibrosis after JAK inhibitor failure and/or progression
- (2020) Robyn M. Scherber et al. BLOOD REVIEWS
- Management of myelofibrosis after ruxolitinib failure
- (2020) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis
- (2020) John Mascarenhas et al. JOURNAL OF MEDICAL ECONOMICS
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
- (2020) Moshe Talpaz et al. LEUKEMIA
- Survival following allogeneic transplant in patients with myelofibrosis
- (2020) Krisstina Gowin et al. Blood Advances
- Fedratinib in myelofibrosis
- (2020) Ann Mullally et al. Blood Advances
- Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
- (2020) Sarah Bassiony et al. Therapeutics and Clinical Risk Management
- Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
- (2020) Andrew T. Kuykendall et al. Cancers
- Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
- (2020) Prithviraj Bose et al. Cancers
- ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
- (2020) Stephen T. Oh et al. Blood Advances
- Bone morphogenetic protein signaling in inflammation
- (2019) David H Wu et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
- (2019) Nico Gagelmann et al. BLOOD
- Anemia of Inflammation
- (2019) Tomas Ganz NEW ENGLAND JOURNAL OF MEDICINE
- Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
- (2019) Prithviraj Bose Expert Opinion on Orphan Drugs
- Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib
- (2019) Ruben A Mesa et al. BLOOD
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
- (2019) Raajit K. Rampal et al. BLOOD
- Mutational profiling in myelofibrosis: implications for management
- (2019) Prithviraj Bose et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
- (2018) Maura Nicolosi et al. LEUKEMIA
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Management of Myelofibrosis-Related Cytopenias
- (2018) Prithviraj Bose et al. Current Hematologic Malignancy Reports
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
- (2016) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
- (2016) Mohamed Shanavas et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
- (2016) Haifa Kathrin Al-Ali et al. LEUKEMIA & LYMPHOMA
- Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
- (2016) D Barraco et al. Blood Cancer Journal
- The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
- (2016) V. Gupta et al. HAEMATOLOGICA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) A. M. Vannucchi et al. ANNALS OF ONCOLOGY
- Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
- (2015) Greg L. Plosker DRUGS
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
- (2013) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Systemic Iron Homeostasis
- (2013) Tomas Ganz PHYSIOLOGICAL REVIEWS
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
- (2010) C. Elena et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism
- (2009) Billy Andriopoulos Jr et al. NATURE GENETICS
- Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines
- (2008) Oliver Bock et al. AMERICAN JOURNAL OF PATHOLOGY
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Low-dose thalidomide in myelofibrosis
- (2008) R. Weinkove et al. HAEMATOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation